IPP Bureau

Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv

By IPP Bureau - June 28, 2022

Strengthens investment in channels of the future to expand patient reach

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

By IPP Bureau - June 28, 2022

First and only PARP inhibitor to improve invasive disease-free survival in patients

50%+ patients delay cataract surgeries in India: Survey
50%+ patients delay cataract surgeries in India: Survey

By IPP Bureau - June 28, 2022

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries

PHARMAP 2022 concludes with productive networking of pharma leaders
PHARMAP 2022 concludes with productive networking of pharma leaders

By IPP Bureau - June 28, 2022

The Congress was held on June, 20-21, 2022 in Berlin, Germany

Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma
Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma

By IPP Bureau - June 27, 2022

Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.

Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana
Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana

By IPP Bureau - June 27, 2022

Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

By IPP Bureau - June 27, 2022

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

By IPP Bureau - June 27, 2022

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine

Novartis commits US$ 250 million to the fight against NTDs and malaria
Novartis commits US$ 250 million to the fight against NTDs and malaria

By IPP Bureau - June 24, 2022

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.

Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer

By IPP Bureau - June 24, 2022

Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally

Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D

By IPP Bureau - June 24, 2022

Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.

ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP

By IPP Bureau - June 24, 2022

ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.

MEI Pharma appoints Anne Frese as Chief People Officer
MEI Pharma appoints Anne Frese as Chief People Officer

By IPP Bureau - June 24, 2022

Most recently, she served as chief human resources officer at Vyripharm Enterprises.

Mandaviya chairs high level meeting to review COVID-19 status
Mandaviya chairs high level meeting to review COVID-19 status

By IPP Bureau - June 24, 2022

The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases

Silo Pharma expands license agreement and patent portfolio
Silo Pharma expands license agreement and patent portfolio

By IPP Bureau - June 24, 2022

Silo enters into commercial evaluation license agreement for next generation liposomes

Latest Stories

Interviews

Packaging